Marijn Dekkers has resigned his position as president, CEO, and member of the board of directors at Thermo Fisher Scientific to take over as CEO of German drug, chemicals, and life science giant Bayer.
Thermo Fisher has appointed current Chief Operating Officer Marc Casper to become president, CEO, and board member effective Oct. 15.
Dekkers has been with Thermo Fisher for the past nine years, overseeing Thermo Electron's $10.6 billion merger with Fisher Scientific in late 2006.
Casper has been with Thermo as president of its life and laboratory sciences business since 2001. He served as president of the firm's analytical technologies businesses after the merger.
Though Dekkers is leaving Thermo Fisher now, he won't take the helm at Bayer until Oct. 1, 2010, when current CEO Wener Wenning steps down. However, Dekkers will serve as interim CEO of Bayer's healthcare division, taking over for Arthur Higgins, who is leaving "for personal reasons" in the first half of next year.
23andMe Co-founder Linda Avey has left the personal genomics services company to start a foundation that will focus on Alzheimer's disease. The foundation Avey will run will use the 23andMe research platform to search for causes of and treatments for the disease.
Avey's departure was effective Sept. 4, the day the announcement was made.